CN106039094A - Use of bamboo leaf extract in prevention and treatment on alcoholic liver injury - Google Patents
Use of bamboo leaf extract in prevention and treatment on alcoholic liver injury Download PDFInfo
- Publication number
- CN106039094A CN106039094A CN201610633775.1A CN201610633775A CN106039094A CN 106039094 A CN106039094 A CN 106039094A CN 201610633775 A CN201610633775 A CN 201610633775A CN 106039094 A CN106039094 A CN 106039094A
- Authority
- CN
- China
- Prior art keywords
- hours
- adds
- leachate
- bamboo leaf
- stirring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000284 extract Substances 0.000 title claims abstract description 46
- 235000017166 Bambusa arundinacea Nutrition 0.000 title claims abstract description 24
- 235000017491 Bambusa tulda Nutrition 0.000 title claims abstract description 24
- 241001330002 Bambuseae Species 0.000 title claims abstract description 24
- 235000015334 Phyllostachys viridis Nutrition 0.000 title claims abstract description 24
- 239000011425 bamboo Substances 0.000 title claims abstract description 24
- 231100000753 hepatic injury Toxicity 0.000 title claims abstract description 11
- 230000001476 alcoholic effect Effects 0.000 title claims abstract description 10
- 206010067125 Liver injury Diseases 0.000 title claims abstract description 9
- 230000002265 prevention Effects 0.000 title abstract description 3
- 229930003944 flavone Natural products 0.000 claims abstract description 14
- 235000011949 flavones Nutrition 0.000 claims abstract description 14
- 150000002213 flavones Chemical class 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 7
- 238000002360 preparation method Methods 0.000 claims abstract description 5
- 235000013305 food Nutrition 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 64
- 238000003756 stirring Methods 0.000 claims description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- 239000000843 powder Substances 0.000 claims description 24
- 238000010438 heat treatment Methods 0.000 claims description 12
- 102000004139 alpha-Amylases Human genes 0.000 claims description 11
- 108090000637 alpha-Amylases Proteins 0.000 claims description 11
- 229940024171 alpha-amylase Drugs 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 108010059892 Cellulase Proteins 0.000 claims description 9
- 229940106157 cellulase Drugs 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 7
- 229920001353 Dextrin Polymers 0.000 claims description 6
- 239000004375 Dextrin Substances 0.000 claims description 6
- 239000012141 concentrate Substances 0.000 claims description 6
- 235000019425 dextrin Nutrition 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 229940088598 enzyme Drugs 0.000 claims description 5
- 239000011259 mixed solution Substances 0.000 claims description 3
- 239000013049 sediment Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 10
- 239000000243 solution Substances 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- -1 flavone compound Chemical class 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 3
- 108010082126 Alanine transaminase Proteins 0.000 description 3
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 3
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 3
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 3
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 3
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 3
- 235000005493 rutin Nutrition 0.000 description 3
- 229960004555 rutoside Drugs 0.000 description 3
- 239000002893 slag Substances 0.000 description 3
- BNGXYYYYKUGPPF-UHFFFAOYSA-M (3-methylphenyl)methyl-triphenylphosphanium;chloride Chemical compound [Cl-].CC1=CC=CC(C[P+](C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 BNGXYYYYKUGPPF-UHFFFAOYSA-M 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- 102000003929 Transaminases Human genes 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
- 206010009208 Cirrhosis alcoholic Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-DVKNGEFBSA-N alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-DVKNGEFBSA-N 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000012928 buffer substance Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 229940124447 delivery agent Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 235000009048 phenolic acids Nutrition 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to the field of pharmacy and especially relates to a use of bamboo leaf extract in preparation of a drug or food for prevention and treatment on alcoholic liver injury. The bamboo leaf extract contains 2-10wt% of total flavones from bamboo leaves.
Description
Technical field
The present invention relates to Medicines and Health Product field, particularly relate to the medical usage of a Plant Extracts.
Background technology
Bamboo has long edible and medicinal history in China, and the medical treatment of bamboo is in the public eye already with health-care effect.
According to medical book record, Folium Bambusae have the cool heart delay spleen, clearly quench the thirst, the function of heat-clearing and toxic substances removing.
Folium Bambusae contains substantial amounts of flavone compound and bioactive polysaccharide and other effective ingredient, such as phenolic acids chemical combination
Thing, anthraquinone analog compound, terpene lactone, the extraordinary material such as aminoacid and bioactive peptide, manganese, zinc, selenium.
The most conventional Folium Bambusae extraction process has decocting in water extraction, microwave radiation exaraction, organic solvent extraction and macroporous resin
Purifies and separates etc., final extract is mainly flavonoid.
Alcoholic liver injury (alcoholic liver disease) shows various, and the initial stage is usually expressed as fatty liver, enters
And alcoholic hepatitis, alcoholic fibrosis and alcoholic cirrhosis can be developed into.Extensive liver can be induced thin when serious excessive drinking
Even the downright bad liver failure of born of the same parents.
Summary of the invention
The purpose of the present invention aims to provide the medical usage of a kind of Folium Bambosae extract.
Specifically, the invention provides a kind of Folium Bambosae extract and prevent and treat medicine or the food of alcoholic liver injury in preparation
In application, described Folium Bambosae extract contains 2～10wt% Folium Bambusae total flavones.
In a preference, the content of described Folium Bambusae total flavones is 5.8wt%.
In another preference, described Folium Bambosae extract comprises the following steps:
Step one, is broken to 20～100 mesh by bamboo leaf powder, puts into reactor, and add bamboo leaf powder weight 2～4 times amount uses second
The mixed solution that alcohol is formed according to the volume ratio of 2:1 with water, soaks 4～12 hours；
Step 2, adds the water of bamboo leaf powder weight 2～4 times amount in a kettle., is heated with stirring to reactor temperature and reaches
To 40～45 DEG C, adding cellulase, the consumption of described cellulase is that every kilogram of bamboo leaf powder adds cellulase 15～500,000
Unit, stirs with the rotating speeds of 50～100 turns per minute, react 12～36 hours, control reactor temperature 45～55 DEG C it
Between；
Step 3, stop heating and stirring, staticly settle 4～8 hours, leach leachate M standby, retain solid residue in
In reactor；
Step 4, adds and the water of leachate M equivalent in a kettle., be heated with stirring to reactor temperature reach 40～
45 DEG C, the dextrin that will be equivalent to bamboo leaf powder weight 0.08～0.15 times amount mixes according to the weight ratio of 1:2 with water, dissolves, and adds α
Amylase, the consumption of described alpha amylase is that every kilogram of dextrin adds alpha amylase 20,000 unit, stirs, is thrown by this mixture
Enter reactor, stir with the rotating speeds of 50～100 turns per minute, react 12～36 hours, control reactor temperature 45～55
Between DEG C；
Step 5, stops heating and stirring, staticly settles 4～8 hours, leach leachate N；
Step 6, mixes leachate M and leachate N, reclaims ethanol, concentrates, and is dried.
The details of various aspects of the present invention will be able to detailed description in chapters and sections subsequently.By hereafter and claim
Description, the feature of the present invention, purpose and advantage will become apparent from.
Accompanying drawing explanation
Fig. 1 is the mouse feeding scheme of embodiment 4
Fig. 2 is each group mice serum aspartate amino transferase contrast of embodiment 4
Fig. 3 is each group mice alanine aminotransferase contrast of embodiment 4
Fig. 4 is each group mouse liver triglyceride contrast of embodiment 4
Detailed description of the invention
The appearance part of the present invention is to have been surprisingly found that based on such a: extract the Folium Bambusae obtained by the new technology of the present invention
Extract can effectively treat Alcoholic Hepatic Injury.Therefore, this plant extract can be expected to be developed into a kind of prevention or
Person treats the medicine of alcoholic liver injury.
Specifically, the Folium Bambosae extract of the present invention can be extracted from Folium Bambusae by the following new technology of the present invention and obtain:
Step one, is broken to 20～100 mesh by bamboo leaf powder, puts into reactor, and add bamboo leaf powder weight 2～4 times amount uses second
The mixed solution that alcohol is formed according to the volume ratio of 2:1 with water, soaks 4～12 hours；
Step 2, adds the water of bamboo leaf powder weight 2～4 times amount in a kettle., is heated with stirring to reactor temperature and reaches
To 40～45 DEG C, adding cellulase, the consumption of described cellulase is that every kilogram of bamboo leaf powder adds cellulase 15～500,000
Unit, stirs with the rotating speeds of 50～100 turns per minute, react 12～36 hours, control reactor temperature 45～55 DEG C it
Between；
Step 3, stop heating and stirring, staticly settle 4～8 hours, leach leachate M standby, retain solid residue in
In reactor；
Step 4, adds and the water of leachate M equivalent in a kettle., be heated with stirring to reactor temperature reach 40～
45 DEG C, the dextrin that will be equivalent to bamboo leaf powder weight 0.08～0.15 times amount mixes according to the weight ratio of 1:2 with water, dissolves, and adds α
Amylase, the consumption of described alpha amylase is that every kilogram of dextrin adds alpha amylase 20,000 unit, stirs, is thrown by this mixture
Enter reactor, stir with the rotating speeds of 50～100 turns per minute, react 12～36 hours, control reactor temperature 45～55
Between DEG C；
Step 5, stops heating and stirring, staticly settles 4～8 hours, leach leachate N；
Step 6, mixes leachate M and leachate N, reclaims ethanol, concentrates, and is dried.
Confirming after testing, in the Folium Bambosae extract of the present invention, the content of Folium Bambusae total flavones is 2～10wt%, preferred content
For 5.8wt%.
The Folium Bambosae extract of the present invention can be used alone or uses with the form of pharmaceutical composition.Pharmaceutical composition includes
The Folium Bambosae extract of the present invention and pharmaceutically suitable carrier as active component.It is preferred that the pharmaceutical composition of the present invention contains
The Folium Bambosae extract of the present invention as active component of 0.1-99.9% percentage by weight." pharmaceutically suitable carrier " will not destroy this
The pharmaceutical active of Folium Bambosae extract of invention, its effective dose simultaneously, consumption when can play pharmaceutical carrier effect is to human body
Nontoxic.
Described pharmaceutically suitable carrier includes but not limited to: soft phospholipid, aluminium stearate, aluminium oxide, ion exchange material, self emulsifying
Drug delivery system, tween or other surfactants, serum albumin, buffer substance such as phosphate, glycine, sorbic acid,
Water, salt, electrolyte such as sulfate protamine, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salt, magnesium silicate, satisfied fatty acid
Partial glyceride mixtures etc..
Other conventional excipient substance such as binding agent (such as microcrystalline Cellulose), filleies are (such as starch, glucose, anhydrous lactitol
Sugar and lactose beadlet), disintegrating agent is (such as cross-linked pvp, crosslinked carboxymethyl fecula sodium, cross-linking sodium carboxymethyl cellulose, low-substituted hydroxypropyl
Base cellulose), lubricant (such as magnesium stearate) and absorption enhancer, absorption carrier, flavouring agent, sweeting agent, excipient, dilution
Agent, wetting agent etc..
The Folium Bambosae extract of the present invention and its pharmaceutical composition can be prepared by this area conventional method and can pass through intestinal
Road or non-bowel or topical routes.Oral formulations includes capsule, tablet, oral liquid, granule, pill, powder, pellet
Agent, unguentum etc.；Non-intestinal drug delivery agent includes injection etc.；Local administration preparation includes cream, patch, ointment, spray
Deng.It is preferably oral formulations.
The route of administration of the Folium Bambosae extract of the present invention and its pharmaceutical composition can be oral, Sublingual, percutaneous, through flesh
Meat or subcutaneous, mucocutaneous, vein, urethra, vagina etc..
In addition to making medicament, also can add antioxidant, pigment, enzyme preparation etc. in the Folium Bambosae extract of the present invention
Various food additive, make health food by the conventional method of this area.
Below in conjunction with specific embodiment, the present invention is expanded on further.Should be understood that these embodiments are merely to illustrate the present invention
Rather than restriction the scope of the present invention.The experimental technique of unreceipted actual conditions in the following example, generally according to conventional strip
Part or according to the condition proposed by manufacturer.Unless otherwise indicated, the most all of percent, ratio, ratio or number are pressed
Weight meter.
Unless otherwise defined, the meaning that all specialties used in literary composition are familiar with one skilled in the art with scientific words
Justice is identical.Additionally, any method similar or impartial to described content and material all can be applicable in the inventive method.Wen Zhong
Described preferable implementation only presents a demonstration with material and is used.
The features described above that the present invention mentions, or the feature that embodiment is mentioned can be in any combination.Patent specification is taken off
The all features shown can be with any composition forms use, and each feature disclosed in description any can provide phase
The alternative characteristics of purpose same, impartial or similar replaces.Therefore except having special instruction, disclosed feature to be only impartial or similar
The general example of feature.
Embodiment 1 prepares Folium Bambosae extract A
Step one, is broken to 40 mesh by bamboo leaf powder, takes 120kg Folium Bambusae dry powder and puts into reactor, adds 360kg alcohol,diluted
(alcohol: water=2:1), soaks 6 hours；
Step 2, adds 360kg water in a kettle., is heated with stirring to reactor temperature and reaches 45 DEG C, add fiber
Element enzyme 60,000,000 unit, stirs with the rotating speeds of 50 turns per minute, reacts 24 hours, controls reactor temperature at 50 DEG C；
Step 3, stops heating and stirring, staticly settles 6 hours, leach leachate M 500kg standby, retain solid residual
Slag is in reactor；
Step 4, adds 500kg water in a kettle., is heated with stirring to reactor temperature and reaches 45 DEG C, stuck with paste by 12kg
Essence mixes with 24kg water, dissolves, and adds alpha amylase 240,000 unit, stirs, and this mixture is put into reactor, with every point
The rotating speed stirring that clock is 50 turns, reacts 24 hours, controls reactor temperature at 50 DEG C；
Step 5, stops heating and stirring, staticly settles 6 hours, leach leachate N 450kg；
Step 6, mixes leachate M and leachate N, reclaims ethanol, concentrates, and is dried to obtain Folium Bambosae extract 18kg.
With the content of total flavones in this Folium Bambosae extract of spectrophotometry:
Weigh 13.2mg rutin, with 60% ethanol constant volume to 25ml volumetric flask as standard solution.
Accurately draw 0,0.4,0.8,1.2,1.6,2.0ml rutin standard solution, put into 10 milliliters of volumetric flasks and (write mark exactly
Note), be separately added into 2.0,1.6,1.2,0.8,0.4,60% ethanol solution of 0ml；Add 5% sodium nitrite solution 0.5ml
Shake up, place 6min；Add 10% aluminum nitrate solution 0.5ml, after placing 6min；Add 4% sodium hydroxide solution 4.0ml, add
60% ethanol constant volume, after shaking up, places 15min；(absorption maximum is found in scanning) measures absorbance at 510nm.Make with 0.0ml
For blank, by the concentration of rutin content as abscissa, vertical coordinate, as absorbance corresponding under finite concentration, makees standard bent
Line.
Total flavones extracts and measures and calculate
Weigh 0.6～0.8g sample powder, add 60ml 60% ethanol and be put in 100ml round-bottomed flask, be placed in water-bath
On, reflux, extract, 60min under the conditions of 70 DEG C.Filtration, constant volume are in 100ml.
Pipette samples amount (adjusting according to the absorbance of sample) 1.0ml, puts into 10 milliliters of volumetric flasks (writing labelling exactly), uses
60% ethanol is added to 2.0ml；Add 5% sodium nitrite solution 0.5ml to shake up, place 6min；Add 10% aluminum nitrate, solution
0.5ml, after placing 6min；Add 4% sodium hydroxide solution 4.0ml, after shaking up, add 60% ethanol constant volume, place 15min；?
Absorbance is measured at 510nm.The content of total flavones is calculated according to standard curve.
General flavone content=A/M*100 × extension rate
A is the content in standard curve.
After testing, the Folium Bambosae extract of the present invention (5.8wt%) Han total flavones 1.05kg.
Embodiment 2 prepares Folium Bambosae extract B
Step one, is broken to 20 mesh by bamboo leaf powder, takes 80kg Folium Bambusae dry powder and puts into reactor, adds 320kg alcohol,diluted
(alcohol: water=2:1), soaks 4 hours；
Step 2, adds 320kg water in a kettle., is heated with stirring to reactor temperature and reaches 40 DEG C, add fiber
Element enzyme 12,000,000 unit, stirs with the rotating speeds of 80 turns per minute, reacts 12 hours, controls reactor temperature at 45 DEG C；
Step 3, stops heating and stirring, staticly settles 4 hours, leach leachate M 450kg standby, retain solid residual
Slag is in reactor；
Step 4, adds 450kg water in a kettle., is heated with stirring to reactor temperature and reaches 45 DEG C, stuck with paste by 6.4kg
Essence mixes with 12.8kg water, dissolves, and adds alpha amylase 12.8 ten thousand unit, stirs, and this mixture is put into reactor, with
The rotating speed stirring of 80 turns per minute, reacts 12 hours, controls reactor temperature at 45 DEG C；
Step 5, stops heating and stirring, staticly settles 4 hours, leach leachate N 500kg；
Step 6, mixes leachate M and leachate N, reclaims ethanol, concentrates, and is dried to obtain Folium Bambosae extract 10.5kg.
After testing (method is with embodiment 1), this Folium Bambosae extract (2.2wt%) Han total flavones 0.23kg.
Embodiment 3 prepares Folium Bambosae extract C
Step one, is broken to 100 mesh by bamboo leaf powder, takes 100kg Folium Bambusae dry powder and puts into reactor, adds 200kg alcohol,diluted
(alcohol: water=2:1), soaks 12 hours；
Step 2, adds 200kg water in a kettle., is heated with stirring to reactor temperature and reaches 40 DEG C, add fiber
Element enzyme 30,000,000 unit, stirs with the rotating speeds of 100 turns per minute, reacts 36 hours, controls reactor temperature at 55 DEG C；
Step 3, stops heating and stirring, staticly settles 8 hours, leach leachate M 300kg standby, retain solid residual
Slag is in reactor；
Step 4, adds 300kg water in a kettle., is heated with stirring to reactor temperature and reaches 45 DEG C, stuck with paste by 15kg
Essence mixes with 30kg water, dissolves, and adds alpha amylase 300,000 unit, stirs, and this mixture is put into reactor, with every point
The rotating speed stirring that clock is 100 turns, reacts 36 hours, controls reactor temperature at 55 DEG C；
Step 5, stops heating and stirring, staticly settles 8 hours, leach leachate N 350kg；
Step 6, mixes leachate M and leachate N, reclaims ethanol, concentrates, and is dried to obtain Folium Bambosae extract 12.5kg.
After testing (method is with embodiment 1), this Folium Bambosae extract (9.6wt%) Han total flavones 1.2kg.
The treatment Alcoholic Hepatic Injury test of embodiment 4 Folium Bambosae extract
One, animal prepares
48 mices are randomly divided into 6 groups, often group 8, numbering G1, G2, G3, G4, G5, G6, respectively blank group
With ethanol group and 4 test group, often 10 mices of group.
Two, process of the test
Folium Bambosae extract A, B and C (preparing as embodiment 1,2 and 3 respectively) of the present invention are made into respectively as listed by table 1 below
Concentration, feeds 3 weeks altogether.Feed with the Lieber-Decarli liquid mice grain that Dyets company produces, feeding and dosage regimen
See Fig. 1, table 1.Testing first 5 days, every day feeds mice with liquid feed, tests the 6th day and starts continuous 10 days, and naive mice depends on
Old feeding with liquid feed, ethanol group and test group are added the ethanol of 5% in feedstuff and are fed, simultaneously at the drinking water of test group
The Folium Bambosae extract of the corresponding percentage ratio of middle interpolation, in the last day of test, to ethanol group and test group by 35% ethanol gavage,
Blank group is with maltodextrin gavage, and gavage is after 9 hours, and anesthetized mice takes blood and other tissues to be measured, and freezen protective is stand-by.
Table 1 mice group dosage
| Group | Feeding medicine | Concentration mg/mL |
| G1 | Blank group | 0 |
| G2 | Ethanol group | 0 |
| G3 | Folium Bambosae extract A | 5% |
| G3 | Folium Bambosae extract B | 3% |
| G5 | Folium Bambosae extract B | 5% |
| G6 | Folium Bambosae extract C | 5% |
Three, experimental result
1, AST, ALT measure
Performance rate method is used to measure mice serum aspartate amino transferase (AST), alanine aminotransferase
(ALT), test kit is purchased from Shanghai Shensuo Youfu Medical Diagnosis Products Co., Ltd..Result is as shown in Figure 2 and Figure 3.
2, triglyceride measures
Using enzymatic assays mouse liver triglyceride, test kit helps the good fortune limited public affairs of medical diagnosis articles for use purchased from Shanghai claim
Department.Result is as shown in Figure 4.
Four, conclusion:
Result of the test shows: compared with blank group, and ethanol can result in liver injury, and (serum transaminase raises, liver
Dirty triglyceride raises), the Folium Bambosae extract of the present invention of various dose can alleviate the serum transaminase rising that ethanol causes
And fatty liver, it was demonstrated that the liver injury that ethanol is caused by the Folium Bambosae extract of the present invention has certain treatment function.
Many aspects involved in the present invention have been done as explained above.However, it should be understood that without departing from present invention spirit
Putting, those skilled in the art can carry out equivalent to it and change and modify, and described change and modification fall into the application equally before
The coverage of claims.
Claims (3)
1. Folium Bambosae extract application in the medicine or food of preparation preventing and treating alcoholic liver injury, described Folium Bambosae extract contains
2～10wt% Folium Bambusae total flavones.
2. the application of Folium Bambosae extract as claimed in claim 1, it is characterised in that the content of described Folium Bambusae total flavones is
5.8wt%.
3. the application of Folium Bambosae extract as claimed in claim 1, it is characterised in that described Folium Bambosae extract is made by the following method
:
Step one, is broken to 20～100 mesh by bamboo leaf powder, puts into reactor, add bamboo leaf powder weight 2～4 times amount with ethanol with
The mixed solution that water is formed according to the volume ratio of 2:1, soaks 4～12 hours；
Step 2, adds the water of bamboo leaf powder weight 2～4 times amount in a kettle., is heated with stirring to reactor temperature and reaches 40
～45 DEG C, adding cellulase, the consumption of described cellulase is that every kilogram of bamboo leaf powder adds cellulase 15～500,000 unit,
Stir with the rotating speeds of 50～100 turns per minute, react 12～36 hours, control reactor temperature between 45～55 DEG C；
Step 3, stops heating and stirring, staticly settles 4～8 hours, leach leachate M standby, retains solid residue in reaction
In still；
Step 4, adds the water with leachate M equivalent in a kettle., is heated with stirring to reactor temperature and reaches 40～45
DEG C, the dextrin that will be equivalent to bamboo leaf powder weight 0.08～0.15 times amount mixes according to the weight ratio of 1:2 with water, dissolves, and adds α and forms sediment
Powder enzyme, the consumption of described alpha amylase is that every kilogram of dextrin adds alpha amylase 20,000 unit, stirs, is put into by this mixture
Reactor, stirs with the rotating speeds of 50～100 turns per minute, reacts 12～36 hours, controls reactor temperature at 45～55 DEG C
Between；
Step 5, stops heating and stirring, staticly settles 4～8 hours, leach leachate N；
Step 6, mixes leachate M and leachate N, reclaims ethanol, concentrates, and is dried.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610633775.1A CN106039094B (en) | 2016-08-04 | 2016-08-04 | Application of bamboo leaf extract in preventing and treating alcoholic liver injury |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610633775.1A CN106039094B (en) | 2016-08-04 | 2016-08-04 | Application of bamboo leaf extract in preventing and treating alcoholic liver injury |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106039094A true CN106039094A (en) | 2016-10-26 |
| CN106039094B CN106039094B (en) | 2019-12-24 |
Family
ID=57480343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610633775.1A Expired - Fee Related CN106039094B (en) | 2016-08-04 | 2016-08-04 | Application of bamboo leaf extract in preventing and treating alcoholic liver injury |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106039094B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017128941A1 (en) * | 2016-01-29 | 2017-08-03 | 上海海中实业有限公司 | Bamboo leaf extract and preparation method and use thereof |
| CN107951030A (en) * | 2017-12-04 | 2018-04-24 | 浙江农林大学 | A kind of compound granule with Antialcoholic liver-protecting and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101380427A (en) * | 2008-09-02 | 2009-03-11 | 上海汉篁生物技术有限公司 | Bamboo leaves standard extract prepared by two-step enzyme method |
| CN101391060A (en) * | 2008-11-05 | 2009-03-25 | 中国林业科学研究院林产化学工业研究所 | Preparation method of bamboo leaf flavone |
| CN101531904A (en) * | 2009-05-05 | 2009-09-16 | 国际竹藤网络中心 | Bamboo leaves extract, preparing method and purpose thereof |
| CN103656301A (en) * | 2013-12-17 | 2014-03-26 | 新乡医学院 | Application of Xinnaojia formula to preparation of liver protection medicine |
-
2016
- 2016-08-04 CN CN201610633775.1A patent/CN106039094B/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101380427A (en) * | 2008-09-02 | 2009-03-11 | 上海汉篁生物技术有限公司 | Bamboo leaves standard extract prepared by two-step enzyme method |
| CN101391060A (en) * | 2008-11-05 | 2009-03-25 | 中国林业科学研究院林产化学工业研究所 | Preparation method of bamboo leaf flavone |
| CN101531904A (en) * | 2009-05-05 | 2009-09-16 | 国际竹藤网络中心 | Bamboo leaves extract, preparing method and purpose thereof |
| CN103656301A (en) * | 2013-12-17 | 2014-03-26 | 新乡医学院 | Application of Xinnaojia formula to preparation of liver protection medicine |
Non-Patent Citations (2)
| Title |
|---|
| 田永利，等: ""总黄酮类化合物含量测定方法和药理作用研究进展"", 《河北医药》 * |
| 赵洪，等: ""纤维素酶提取竹叶黄酮工艺初步研究"", 《广州化工》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017128941A1 (en) * | 2016-01-29 | 2017-08-03 | 上海海中实业有限公司 | Bamboo leaf extract and preparation method and use thereof |
| CN107951030A (en) * | 2017-12-04 | 2018-04-24 | 浙江农林大学 | A kind of compound granule with Antialcoholic liver-protecting and preparation method thereof |
| CN107951030B (en) * | 2017-12-04 | 2021-01-01 | 浙江农林大学 | Compound granule with functions of dispelling effects of alcohol and protecting liver and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106039094B (en) | 2019-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100566714C (en) | A kind of Herba Lycopodii serrati composition and method of making the same that contains huperzine A, second composite parts | |
| CN105687826A (en) | Bamboo leaf extract as well as preparation method and application thereof | |
| CN100364570C (en) | Medicinal composition with blood sugar reducing action and its preparing method | |
| CN107362194B (en) | Compound celery seed and sophora flower bud extract and medical application thereof | |
| JP2009522382A (en) | Composition for prevention and treatment of liver diseases comprising liquiritigenin | |
| CN101033245B (en) | Preparation method and application of pedunculoside | |
| CN108042503B (en) | High-efficiency potassium sodium dehydroandroan drographolide succinate enteric-coated tablet and preparation method thereof | |
| EP2221058B1 (en) | Antimelancholic medicine prepared with jujube camp materials | |
| CN106039094A (en) | Use of bamboo leaf extract in prevention and treatment on alcoholic liver injury | |
| CN101468054A (en) | Wild chrysanthemum effective component composition, preparation method and use thereof as well as medicinal preparation containing the same | |
| CN100375614C (en) | Dripping pills with jaundice eliminating liver protecting functions and its preparation method | |
| CN101002791B (en) | Traditional Chinese medicine composition for treating cerebrovascular disease, and its preparing method | |
| CN101152233B (en) | Pharmaceutical composition of snakegourd fruit and folium ginkgo | |
| JP3204348B2 (en) | Arteriosclerosis inhibitor and food or medicine containing it | |
| CN102579530A (en) | Preparation method of aralia taibaiensis total saponin having diabetes mellitus resisting effect and medicament | |
| TWI334783B (en) | Pharmaceutical composition for facilitating the reduction of blood-alcohol concentration after alcohol intake | |
| CN105012294B (en) | New application of the ellagic acid compounds in treatment antihyperuricemic disease drug is prepared | |
| CN100367938C (en) | Sihuang intense heat purging dripping pill and its preparing method | |
| CN100358496C (en) | 'Xingnaojing' dripping pills for treating cephalitis and hepatic coma and preparation process thereof | |
| CN106344600A (en) | Novel application of hesperidin and pharmaceutical composition containing hesperidin | |
| CN105687225B (en) | A kind of pharmaceutical composition for treating irritable bowel syndrome and its preparation method and application | |
| CN100406003C (en) | Dripping pills of abastard speedwell and its preparation process | |
| CN100453073C (en) | Compound radical lobelia dripping pill and its preparing method | |
| CN101167763B (en) | Monascus and total ginkgolide composition for preventing and treating cardiovascular and cerebrovascular diseases | |
| CN100486598C (en) | Bupleurum root asarum herb dripping pill and its preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20191224 Termination date: 20210804 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |